Home > Oncology > Clinical score helps gauge benefit from radionuclide therapy for NETs

Clinical score helps gauge benefit from radionuclide therapy for NETs


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Network Open
Reuters Health - 19/01/2022 - A validation study supports the use of a clinical scoring system to anticipate whether patients with well-differentiated neuroendocrine tumors (WD NETs) will benefit from peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-dotatate. Despite the benefit from 177Lu-dotatate for patients with WD NETs, "questions remain about when to sequence the therapy for patients in relation to other available therapies, and which patients are optimal candidates for the therapy," Dr. Satya Das of Vanderbilt-Ingram Cancer Center and University Medical Center in Nashville, Tennessee, and colleagues point out in JAMA Network Open. The clinical score (CS) they developed includes five factors (each given a score of zero, one or two): 1) symptoms necessitating treatment (two points for Grade 2+ symptoms, one point for Grade 1 symptoms); 2) tumor bulk in critical organs; 3) non-PRRT treatments available based on primary tumor origin; 4) peri...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on